Hormonal IUD (Mirena/Kyleena) Pipeline, FDA Status, and What's Next for Levonorgestrel IUDs

What the FDA Has Actually Approved, and When

The FDA has approved four distinct levonorgestrel intrauterine systems (LNG-IUS), each with a different hormone load, frame size, and duration. Knowing which device is which matters because the labels differ meaningfully, and so do the best candidates for each.

Mirena: The Original and Most Studied

Bayer's Mirena (52 mg levonorgestrel) was first approved by the FDA in December 2000 for contraception. In 2009, the FDA expanded the label to include treatment of heavy menstrual bleeding (HMB) in women who choose intrauterine contraception. In 2022, the FDA extended Mirena's approved duration from 5 years to 8 years, based on clinical data submitted by Bayer showing continued contraceptive efficacy through year 8.

The drug releases approximately 20 micrograms of levonorgestrel per day initially, declining to around 10 mcg/day after 5 years. That declining local-release curve is why extended-duration labeling required new data, not simply a re-review of the original submission.

Kyleena, Liletta, and Skyla

Kyleena (19.5 mg LNG), also from Bayer, received FDA approval in September 2016. It releases roughly 17.5 mcg/day initially, declining to 7.4 mcg/day by year 5. Its frame is slightly narrower than Mirena's, which may matter for women with a smaller uterine cavity, though Skyla remains the smallest option.

Liletta (52 mg LNG), co-developed by Allergan and Medicines360 and now marketed by Actavis, was approved in February 2015. Its label has been updated progressively: from 3 years to 4 years (2018), then to 6 years (2019), and most recently to 8 years (2022), following data from the ongoing LILETTA trial. The LILETTA study enrolled a higher proportion of nulliparous women and women of color than most prior IUD trials, which is a meaningful step toward a more representative evidence base.

Skyla (13.5 mg LNG) was approved in January 2013. It has the smallest frame (28 mm x 30 mm versus 32 mm x 32 mm for Mirena), releases 14 mcg/day initially, and is labeled for 3 years. It was designed with nulliparous and adolescent patients in mind, though none of the LNG-IUS devices carry an age restriction in their labels.

What the Current Labels Actually Say

Approved Indications and Who Is (and Is Not) Included

The Mirena prescribing information lists two FDA-approved indications: intrauterine contraception for up to 8 years, and treatment of heavy menstrual bleeding in women who opt for intrauterine contraception. Kyleena, Liletta, and Skyla are labeled for contraception only; none carry the HMB indication.

ACOG Committee Opinion 735 states that long-acting reversible contraception, including IUDs, should be offered as first-line contraceptive options for adolescents. This effectively widens the real-world population well beyond the typical trial enrollees.

Contraindications the Label Specifies

The current Mirena label lists absolute contraindications including known or suspected pregnancy, unexplained uterine bleeding, uterine or cervical malignancy, untreated acute cervicitis or endometritis, uterine anomaly distorting the cavity, and allergy to any component. A prior ectopic pregnancy is not a contraindication in the current label, though it remains a risk factor to discuss.

The Ectopic Pregnancy Warning

All LNG-IUS labels include a boxed warning section on ectopic pregnancy. Because these devices are so effective at preventing intrauterine pregnancy, the proportion of any pregnancies that do occur and are ectopic is higher than in the general population. Absolute ectopic risk is lower with an IUD in place than with no contraception, but if pregnancy is suspected during IUD use, ectopic location must be ruled out promptly. This nuance is worth understanding: the device does not cause ectopic pregnancy; it simply does not protect against it as reliably as it protects against intrauterine implantation.

Pregnancy, Lactation, and Contraception Considerations

This section is required reading if you are pregnant, recently postpartum, breastfeeding, or planning a pregnancy.

Use During Pregnancy: Contraindicated

All four LNG-IUS devices are contraindicated for insertion during known or suspected pregnancy. If a device is in place and pregnancy occurs, removal is recommended because continuation of pregnancy with an IUD in situ carries risks including septic abortion, premature labor, and preterm delivery. Removal itself also carries a risk of pregnancy loss. Women should be counseled about both risks so they can make an informed decision.

Levonorgestrel is a progestin. When used as emergency contraception (a single high oral dose), it does not disrupt an established pregnancy. The chronic low-dose local release from an IUD is far smaller still. No teratogenic signal specific to levonorgestrel IUDs has been identified in post-market surveillance, but the data from in-situ pregnancies that continue to term is limited.

Postpartum Insertion

The WHO Medical Eligibility Criteria and ACOG both support LNG-IUS insertion from 4 weeks postpartum onward (MEC Category 2 for <4 weeks postpartum, Category 1 for 4 weeks and beyond). Immediate postpartum insertion (within 10 minutes of placental delivery) is an option some centers offer, though expulsion rates are higher than with interval insertion.

Breastfeeding Compatibility

Levonorgestrel transfers into breast milk in small amounts, but systemic absorption from an IUD is already far lower than from oral progestin-only pills. Studies to date have not shown adverse effects on milk volume, milk composition, or infant growth with LNG-IUS use during lactation. The American Academy of Pediatrics and WHO both classify progestin-only contraceptives as compatible with breastfeeding. This makes the LNG-IUS a particularly useful option for postpartum women who want highly effective contraception without estrogen-related concerns about milk supply.

Fertility Return After Removal

Fertility returns quickly after LNG-IUS removal. In the key Mirena trials, the 12-month pregnancy rate after removal was over 79%, consistent with baseline fertility expectations for the age group studied. The device does not impair future fertility.

Sex-Specific Physiology: How Hormonal Status Changes the Picture

Reproductive Years

During the reproductive years, LNG-IUS works through three primary mechanisms: local endometrial suppression, thickening of cervical mucus, and, at higher doses (Mirena and Liletta), partial suppression of ovulation. A 2018 study in Contraception found that ovulation suppression with the 52 mg devices is inconsistent and declines over time, meaning the primary contraceptive mechanism shifts progressively toward the local endometrial and cervical effects. For most women of reproductive age, systemic progestin exposure remains low enough that cycle changes are the main hormonal effect they notice.

PCOS and Hormonal Acne

Women with polycystic ovary syndrome often have heavy, irregular periods, and the LNG-IUS is a reasonable tool for cycle management in this group. It does not treat the underlying androgen excess of PCOS, and it may not improve androgen-driven symptoms like acne or hirsutism. A combined oral contraceptive pill or spironolactone addresses the androgen component more directly. The LNG-IUS is most useful in PCOS when the primary goal is endometrial protection or HMB control rather than hormonal regulation of the full PCOS syndrome.

Perimenopause

This is where the evidence becomes thinner and extrapolation becomes necessary. Perimenopausal women face irregular, often heavy bleeding as ovarian function fluctuates. The Mirena label does not specify an upper age limit, and ACOG Practice Bulletin 141 discusses the LNG-IUS as a progestogenic component of menopausal hormone therapy, protecting the endometrium in women using systemic estrogen. The device can remain in place through the menopausal transition if it was inserted in the perimenopausal years and has not reached its labeled duration.

A practical framework for perimenopausal use: if a woman in her late 40s has a Mirena inserted primarily for HMB or contraception, and she later starts systemic estrogen therapy for vasomotor symptoms, that same Mirena can serve as her progestogen component, provided it is within its 8-year labeled duration. This avoids the need for a separate oral progestogen. The caveat is that this off-label use of Mirena as the progestogen arm of HRT has supportive data from European studies and is endorsed by The Menopause Society in its 2022 position statement, but it is not an FDA-approved indication in the US.

Endometriosis and Fibroids

The LNG-IUS reduces menstrual blood loss and can reduce endometriosis-related dysmenorrhea. A Cochrane review found the LNG-IUS effective at reducing endometriosis-associated pain compared with expectant management, though direct comparisons with GnRH agonists are limited. For women with fibroids, the picture depends on cavity distortion: submucosal fibroids that distort the uterine cavity are a contraindication to IUD insertion, but intramural or subserosal fibroids are not.

The Heavy Menstrual Bleeding Evidence Base

The LNG-IUS has the strongest evidence of any non-surgical intervention for heavy menstrual bleeding. The ECLIPSE trial (NEJM 2013) randomized 571 women with HMB to either the LNG-IUS or usual medical treatment (tranexamic acid, norethisterone, or combined oral contraceptives). At 2 years, quality-of-life scores were significantly higher in the LNG-IUS group, and the device was more effective at reducing menstrual blood loss. Hysterectomy rates were also lower in the IUD group.

ACOG Practice Bulletin 128 recommends the LNG-IUS as a first-line medical option for HMB in women without structural uterine pathology. The National Institute for Health and Care Excellence (NICE) guideline NG88 similarly lists the LNG-IUS as the first recommended medical treatment for HMB, ahead of tranexamic acid and combined hormonal contraceptives.

Pipeline and Next-Generation Research

Extended Duration Beyond 8 Years

The most active area of research involves pushing approved duration further. Bayer has conducted post-market surveillance and registry studies examining Mirena use beyond 8 years. Preliminary data from the FDA Sentinel System and European post-authorization safety studies suggest contraceptive efficacy may persist beyond the current labeled duration, though the FDA has not approved any LNG-IUS for use beyond 8 years as of mid-2025. Any use beyond labeled duration is off-label and should be discussed explicitly with the patient.

Lower-Dose and Smaller-Frame Devices

The gap between Kyleena and Skyla in terms of duration (5 years versus 3 years) and hormone load points to a design space where a 3-to-4-year device with a very small frame and hormone dose could serve women with smaller uterine cavities, adolescents, and those who want minimal systemic progestin exposure. At least one investigational device in this category has been studied in European Phase 2 trials, though none have reached NDA or 510(k) submission in the US as of this writing.

LNG-IUS as Endometrial Protection in Hormone Therapy

European data, particularly from Scandinavia, have driven interest in formal approval pathways for LNG-IUS as the progestogen arm of HRT. The Mirena as part of HRT has been studied in randomized trials showing endometrial protection equivalent to oral progestogens in menopausal women on systemic estrogen. The Mirena label in several European countries includes this indication. In the US, the FDA has not approved it for this purpose, and Bayer has not submitted an NDA supplement for this indication. This remains an area where US women are relying on off-label clinical practice supported by international evidence.

Biodegradable Frames and Novel Drug Delivery

Research-stage work is exploring IUD frames made from materials that do not require retrieval or that dissolve over a defined period. These are not near regulatory submission. The hormone-delivery challenge is that stable, predictable release over multiple years requires a polymer matrix that has been validated in humans; moving away from the T-shaped polyethylene frame introduces new biocompatibility questions. This is a 5-to-10-year horizon at minimum, not a near-term pipeline option.

Digital Expulsion Detection

A non-pharmacological innovation closer to market involves sensor-equipped IUDs or adjunct ultrasound-based apps designed to detect partial expulsion earlier. Expulsion affects approximately 2-10% of IUD insertions in the first year, with higher rates in nulliparous women and immediately postpartum insertions. Earlier detection would reduce unintended pregnancy from unrecognized expulsion. This is a device-plus-software regulatory pathway (likely Class II medical device), and at least two companies have published feasibility data.

Safety Profile: What Post-Market Data Add to the Label

Pelvic Inflammatory Disease

The LNG-IUS insertion carries a small, time-limited risk of pelvic inflammatory disease (PID), concentrated in the first 20 days after insertion and associated primarily with pre-existing, unrecognized upper genital tract infection at the time of insertion. Screening for gonorrhea and chlamydia before insertion is standard, though the FDA label does not require it as a prerequisite. After the initial 20-day window, IUD use is not associated with increased PID risk in women in mutually monogamous relationships.

Mood and Depression

Post-market pharmacovigilance data, including a 2016 Danish cohort study of over 1 million women, found a modest association between hormonal contraceptive use, including the LNG-IUS, and incident depression diagnosis or antidepressant prescription. The association was present but weaker for the LNG-IUS than for combined oral contraceptives, and causality is not established. Women with a personal or family history of depression should be counseled about this signal and monitored, but the current evidence does not support withholding LNG-IUS from this population absent other contraindications.

Ovarian Cysts

Follicular cysts (functional ovarian cysts) occur more frequently with LNG-IUS use than without. Most are asymptomatic and resolve spontaneously. The Mirena prescribing information notes that approximately 12% of users develop ovarian cysts, compared with 4% in the control population in pre-approval trials. These are almost always follicular cysts, not pathological cysts, and they resolve within 3 months in the majority of cases without intervention.

Insertion Pain

Insertion pain is real and was systematically undercharacterized in the original key trials, which enrolled primarily parous women. A 2015 systematic review in AJOG found that nulliparous women report significantly higher pain scores during IUD insertion than parous women, and that misoprostol cervical priming does not reliably reduce procedural pain despite widespread use. The field is actively studying local anesthesia protocols, paracervical blocks, and topical lidocaine to improve the insertion experience.

Who This Is Right For, and Who Should Consider Something Else

Best Candidates by Life Stage

Reproductive years (18-40s): Women wanting highly effective, low-maintenance contraception, particularly those who want to avoid estrogen (migraine with aura, hypertension, history of thrombosis, breastfeeding). Women with HMB or endometriosis symptoms are particularly well-served by Mirena, which carries the HMB indication and has the most clinical data.

Trying to conceive (TTC) within 1-2 years: A shorter-duration device like Kyleena (5 years) or Skyla (3 years) may feel more psychologically comfortable, though fertility returns equally fast after removal of any LNG-IUS. There is no physiological reason to choose a lower-dose device for faster fertility return.

Postpartum and lactating: LNG-IUS is an excellent choice. Insertion at or after 4 weeks postpartum is supported by ACOG and WHO MEC guidance, and it does not affect milk supply.

Perimenopause: Mirena is the preferred LNG-IUS for perimenopausal women because of its HMB indication and its dual potential role as endometrial protection if systemic estrogen is added. A woman inserting Mirena at age 45 may benefit from it through age 53, covering the full menopausal transition.

Post-menopause: IUD use is not indicated post-menopause for contraception, but Mirena as a component of HRT remains in off-label clinical use in the US and is approved for this indication in some European countries.

Women Who Should Not Use LNG-IUS

Women with current or suspected pregnancy, unexplained uterine bleeding, uterine or cervical malignancy, active pelvic infection, or a uterine cavity that cannot accommodate the device should not use any LNG-IUS. Women with known hypersensitivity to levonorgestrel or to any component of the device should avoid it. Women with severe liver disease should use caution, as progestin metabolism is hepatic, though the very low systemic LNG levels from an IUD make this a lower-risk concern than with oral progestogens.

Evidence Gaps and What We Still Do Not Know

Women over 40, women with obesity (BMI >35), and women with chronic conditions were systematically underrepresented in the key LNG-IUS trials. Efficacy and safety in these groups is extrapolated from the studied populations. The perimenopausal HRT use case has supportive European data but no US FDA approval. The ECLIPSE trial (NEJM 2013) enrolled women aged 25-50, which covers the HMB population reasonably well, but perimenopausal women with fluctuating ovarian function were not separately analyzed.

The long-term endometrial effects beyond 8 years are not characterized by randomized data. Biodegradable or smart IUD technologies are at least a decade from regulatory submission. For now, women and clinicians are working with four well-characterized devices, good safety data up to 8 years, and a growing (though still incomplete) evidence base for use across the full reproductive lifespan.